We've been pretty careful in managing our cash. Our balance sheet is absolutely pristine.

Over the past year we have enjoyed a very productive collaboration with Pfizer, the world's leading research-based pharmaceutical company. We believe that the expansion of this agreement is evidence of our successful development and application of this technology to facilitate the generation of improved production cell lines with altered traits.

As a business person, if I offered you $2.5 million in stock in a private company versus $7.5 million in cash, just in the up-front deal, which would you take? The numbers are unambiguous.

We wanted to do the deal.

Over the past year we have enjoyed a productive collaboration with Pfizer. We believe that the expansion of this agreement is evidence of the application of this technology to facilitate the generation of improved production cell lines with altered traits.

There's no shortage at the moment, but the overall global supply-demand balance is pretty precarious.